Volume 26, Number 3—March 2020
CME ACTIVITY - Synopsis
Clinical Characteristics of Disseminated Strongyloidiasis, Japan, 1975–2017
Table 1
Characteristic | All patients |
Dissemination |
Occult dissemination with meningitis/enteric organisms |
Occult dissemination with culture-negative suppurative meningitis |
||||
---|---|---|---|---|---|---|---|---|
No. patients |
70/70 (100) |
32/70 (45.7) |
12/70 (17.1) |
26/70 (37.1) |
||||
Sex | ||||||||
M | 42 (60) | 19 (59.4) | 6 (50) | 17 (65.3) | ||||
F |
28 (40) |
13 (40.6) |
6 (50) |
9 (34.7) |
||||
Median age, y (range) |
61 (21–96) |
67 (25–96) |
47 (21–84) |
57 (38–92) |
||||
Immunocompromised status | ||||||||
HTLV-1 infection† | 36/40 (90.0) | 17/20 (85.0) | 8/9 (88.9) | 11/11 (100) | ||||
Steroid use | 6 (8.6) | 5 (15.6) | 1 (8.3) | 0 (0) | ||||
Solid organ malignancy | 6 (8.6) | 4 (12.5) | 2 (16.7) | 0 (0) | ||||
Diabetes mellitus | 4 (5.7) | 4 (12.5) | 0 (0) | 0 (0) | ||||
Cirrhosis |
2 (2.9) |
2 (6.3) |
0 (0) |
0 (0) |
||||
Death | 23 (32.9) |
18 (56.3) |
2 (16.7) |
3 (11.5) |
*Values are no. (%) unless indicated. HTLV-1, human T-cell lymphotrophic virus type 1.
†Serologic test for HTLV-1 infection was not available until the 1980s.
Page created: February 19, 2020
Page updated: February 19, 2020
Page reviewed: February 19, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.